Eledon Pharmaceuticals Inc (ELDN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $178.63M
Last updated: Nov 17, 2026 at 11:05 AM ET
Eledon Pharmaceuticals Inc (ELDN) Stock Forecast
Analysts expect Eledon Pharmaceuticals (ELDN) to earn -$0.93 per share in the fiscal year ending Dec 31, 2026. Of 6 analysts, 6 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 6 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$0.93
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.77
- EPS consensus
- Next report
- Mar 17, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.93 | -$1.04 to -$0.77 | 4 |
| Dec 31, 2027 | -$0.77 | -$0.92 to -$0.67 | 3 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.17 | -$0.22 to -$0.01 | 7 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 4 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 2 |
| Fiscal year ending Dec 31, 2027 | 1 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.87.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.93 | -$0.93 | -$0.93 | -$0.93 | -$0.87 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.77 | -$0.77 | -$0.77 | -$0.72 | -$0.72 | N/A |
Frequently Asked Questions About ELDN
What is the ELDN stock forecast?
Consensus analyst estimates put Eledon Pharmaceuticals's EPS at -$0.93 for the fiscal year ending Dec 31, 2026. The consensus rating from 6 analysts is Buy.
How do analysts rate ELDN stock?
Of 6 analysts covering Eledon Pharmaceuticals, 0 rate it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ELDN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.93, with estimates from -$1.04 to -$0.77 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.77, with estimates from -$0.92 to -$0.67 from 3 analysts.
How many analysts cover ELDN?
6 analysts rate Eledon Pharmaceuticals stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ELDN pages: Overview, Earnings, Forecast, Financials, Competitors